From the therapeutic perspective, several clinical studies have performed trials on inhibitors of chemokines or their receptors, such as CXCR2, in patients with DN or DR, and these studies have shown good preliminary results41,42. This evidence concerns the gene CXCR2 and liver dysplastic nodule.